Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 110.28 billion. The enterprise value is 133.88 billion.

Market Cap	110.28B
Enterprise Value	133.88B

Important Dates

The last earnings date was Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Genmab has 61.49 million shares outstanding. The number of shares has decreased by -3.04% in one year.

Current Share Class	61.49M
Shares Outstanding	61.49M
Shares Change (YoY)	-3.04%
Shares Change (QoQ)	+1.68%
Owned by Insiders (%)	1.16%
Owned by Institutions (%)	60.02%
Float	60.76M

Valuation Ratios

The trailing PE ratio is 18.34 and the forward PE ratio is 22.99. Genmab's PEG ratio is 2.13.

PE Ratio	18.34
Forward PE	22.99
PS Ratio	4.66
PB Ratio	2.97
P/TBV Ratio	n/a
P/FCF Ratio	15.09
P/OCF Ratio	14.62
PEG Ratio	2.13

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.10, with an EV/FCF ratio of 18.32.

EV / Earnings	21.86
EV / Sales	5.66
EV / EBITDA	16.10
EV / EBIT	16.84
EV / FCF	18.32

Financial Position

The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.93.

Current Ratio	2.02
Quick Ratio	2.01
Debt / Equity	0.93
Debt / EBITDA	4.15
Debt / FCF	4.72
Interest Coverage	20.49

Financial Efficiency

Return on equity (ROE) is 17.53% and return on invested capital (ROIC) is 16.61%.

Return on Equity (ROE)	17.53%
Return on Assets (ROA)	8.10%
Return on Invested Capital (ROIC)	16.61%
Return on Capital Employed (ROCE)	10.92%
Weighted Average Cost of Capital (WACC)	6.60%
Revenue Per Employee	7.96M
Profits Per Employee	2.06M
Employee Count	2,973
Asset Turnover	0.39
Inventory Turnover	17.63

Taxes

In the past 12 months, Genmab has paid 1.53 billion in taxes.

Income Tax	1.53B
Effective Tax Rate	20.02%

Stock Price Statistics

The stock price has increased by +8.68% in the last 52 weeks. The beta is 0.75, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	+8.68%
50-Day Moving Average	2,001.26
200-Day Moving Average	1,767.47
Relative Strength Index (RSI)	38.46
Average Volume (20 Days)	145,554

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 23.66 billion and earned 6.13 billion in profits. Earnings per share was 97.77.

Revenue	23.66B
Gross Profit	22.15B
Operating Income	7.95B
Pretax Income	7.66B
Net Income	6.13B
EBITDA	8.21B
EBIT	7.95B
Earnings Per Share (EPS)	97.77

Full Income Statement

Balance Sheet

The company has 10.91 billion in cash and 34.51 billion in debt, giving a net cash position of -23.61 billion or -383.91 per share.

Cash & Cash Equivalents	10.91B
Total Debt	34.51B
Net Cash	-23.61B
Net Cash Per Share	-383.91
Equity (Book Value)	37.19B
Book Value Per Share	603.58
Working Capital	9.27B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.54 billion and capital expenditures -235.35 million, giving a free cash flow of 7.31 billion.

Operating Cash Flow	7.54B
Capital Expenditures	-235.35M
Free Cash Flow	7.31B
FCF Per Share	118.87

Full Cash Flow Statement

Margins

Gross margin is 93.60%, with operating and profit margins of 33.60% and 25.89%.

Gross Margin	93.60%
Operating Margin	33.60%
Pretax Margin	32.37%
Profit Margin	25.89%
EBITDA Margin	34.68%
EBIT Margin	33.60%
FCF Margin	30.89%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.04%
Shareholder Yield	3.04%
Earnings Yield	5.55%
FCF Yield	6.63%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 2.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.48
Piotroski F-Score	4